SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Biogen Reports Phase 2 Diranersen Results Showing Slower Decline

Phase 2 CELIA results showed slower clinical decline with investigational diranersen at Week 96. The 60 mg twice-yearly regimen had the largest effects, including a 1.09-point CDR-SB treatment difference; two-year analyses came from an ongoing open-label extension.

BIIB

Biogen reported Phase 2 CELIA results showing slower clinical decline with investigational diranersen at Week 96. The 60 mg twice-yearly regimen showed the largest effects, including a 1.09-point CDR-SB treatment difference; two-year analyses came from an ongoing open-label extension.Material Detai…

Related stories